ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
6
views
0
references
Top references
cited by
2
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
3,988
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
No increase in bone fractures with empaglifl ozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM).
Author(s):
C WANNER
,
RD Toto
,
J Gerich
,
C Wanner
Publication date:
2013
Journal:
J Am Society Nephrol
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Journal of the ASEAN Federation of Endocrine Societies
Data availability:
ScienceOpen disciplines:
Endocrinology & Diabetes
,
Medicine
Comments
Comment on this article
Sign in to comment
Similar content
3,988
Consistent effect of empagliflozin on cardiovascular death in subgroups by type of cardiovascular disease: results from empa-reg outcome
Authors:
Zinman
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
Authors:
BERNARD ZINMAN
,
DAVID H. FITCHETT
,
MICHAELA MATTHEUS
…
Empagliflozin (EMPA) reduces heart failure irrespective of control of blood pressure (BP), low density lipoprotein cholesterol (LDLC), and HbA1c
Authors:
Fitchett
,
D Fitchett
,
J. MCKNIGHT
…
See all similar
Cited by
2
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Authors:
Michael A. Nauck
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Authors:
Matthew J Levine
,
See all cited by